Odyssean LLC Purchases 2,358 Shares of United Therapeutics Corporation $UTHR

Odyssean LLC increased its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 76.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,445 shares of the biotechnology company’s stock after buying an additional 2,358 shares during the quarter. Odyssean LLC’s holdings in United Therapeutics were worth $2,950,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Geneos Wealth Management Inc. raised its holdings in shares of United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in United Therapeutics by 18.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 70 shares during the last quarter. Jump Financial LLC bought a new position in United Therapeutics in the second quarter valued at $277,000. Cerity Partners LLC grew its position in United Therapeutics by 77.3% in the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after purchasing an additional 5,600 shares in the last quarter. Finally, Bank of Nova Scotia increased its stake in United Therapeutics by 6.9% in the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after buying an additional 105 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Trading Down 0.5%

NASDAQ UTHR opened at $487.61 on Friday. United Therapeutics Corporation has a 1-year low of $375.61 and a 1-year high of $609.35. The company has a 50 day moving average of $525.95 and a 200-day moving average of $539.55. The company has a market cap of $20.91 billion, a price-to-earnings ratio of 17.45, a PEG ratio of 2.45 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.United Therapeutics’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $6.41 earnings per share. On average, equities research analysts forecast that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Weiss Ratings cut United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. JPMorgan Chase & Co. upped their price objective on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Morgan Stanley set a $515.00 price objective on United Therapeutics in a report on Thursday, August 6th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Finally, Royal Bank Of Canada lowered their target price on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $646.00.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $540.15, for a total value of $5,401,500.00. Following the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $10,195,871.40. This trade represents a 34.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $545.83, for a total value of $5,185,385.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares in the company, valued at approximately $22,113,210.79. The trade was a 19.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 404,075 shares of company stock worth $214,704,893 over the last three months. 8.60% of the stock is currently owned by insiders.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: The FDA accepted United Therapeutics’ supplemental new drug application for Tyvaso in idiopathic pulmonary fibrosis (IPF). The application is supported by Phase 3 TETON data showing improved lung function and reduced clinical worsening. FDA review is expected to conclude in April 2027, and approval could materially expand Tyvaso’s addressable market. FDA Accepts UTHR’s sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
• Neutral Sentiment: Analysts remain broadly constructive, with a consensus “Moderate Buy” rating and an average price target near $646. However, several firms have recently lowered their targets, indicating that optimism about UTHR’s pipeline and valuation is tempered by execution and growth concerns. Analyst Sentiment on United Therapeutics
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $4.69 million, while EVP Paul Mahon sold 8,300 shares for about $4.00 million. Mahon’s sale reduced his holdings by 15.52%, and the transactions may be weighing on investor sentiment, even though the CEO’s sale was disclosed through an SEC filing and may have been prearranged. United Therapeutics Insider Selling
• Negative Sentiment: The latest quarterly results exceeded EPS expectations, but revenue of $783.3 million fell short of the $804.7 million consensus estimate and declined 1.9% year over year. The revenue weakness, combined with competition affecting pulmonary hypertension therapies, helps explain why investors remain cautious after earnings. United Therapeutics Earnings Performance

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.